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MaBACKGROUND MicroRNA-223 (miR-223) is a hematopoietic lineage cell-speciﬁc microRNA. However, a signiﬁcant
amount of miR-223 has been identiﬁed in vascular smooth muscle cells (VSMCs) and vascular walls that should not have
endogenous miR-223.
OBJECTIVES This study sought to determine the sources of miR-223 in normal and atherosclerotic arteries and the role
of miR-223 in atherogenesis.
METHODS The levels and sources of miR-223 in blood cells (leukocytes and platelets), serum, blood microparticles,
VSMCs, and vascular walls were determined. Both in vivo and in vitro studies were conducted to evaluate miR-223
secretion by blood cells and the ability of miR-223 to enter VSMCs and vascular walls. Subsequent changes in and the
effects of miR-223 levels on serum and arteries in atherosclerotic animals and patients were investigated.
RESULTS Blood cells were able to secrete miR-223 into serum. MicroRNA-223 from blood cells was the most abundant
cell-free miRNA in blood. Blood cell–secreted miR-223 could enter VSMCs and vascular walls, which produced strong
biological effects via its target genes. In both atherosclerotic apolipoprotein-E knockout mice and patients with
atherosclerosis, miR-223 levels were signiﬁcantly increased in serum and atherosclerotic vascular walls. The athero-
sclerotic lesions in apolipoprotein-E knockout mice were exacerbated by miR-223 knockdown. The effect of miR-223
on atherogenesis was veriﬁed using miR-223 knockout mice.
CONCLUSIONS Blood cell–secreted miR-223 enters vascular cells and walls, and appears to play important roles in
VSMC function and atherogenesis. As a novel endocrine genetic signal between blood cells and vascular cells, miR-223
may provide a novel mechanism and new therapeutic target for atherosclerosis. (J Am Coll Cardiol 2015;65:2526–37)
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AB BR E V I A T I O N S
AND ACRONYM S
apo-E = apolipoprotein-E
IGF-1R = insulin-like growth
factor-1 receptor
miRNA = micro ribonucleic
acid
PDGF = platelet-derived
growth factor
qRT-PCR = real-time reverse
transcription-polymerase chain
reaction
VSMC = vascular smooth
muscle cell
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2527atherosclerosis. However, the molecular mechanisms
responsible for atherogenesis induced by blood cells
and any related new therapeutic targets remain to be
deﬁned (1).
Micro-ribonucleic acids (miRNAs) are a class of
endogenous, small, noncoding RNAs that directly
regulate >30% of genes in a cell (2,3). Once thought to
exist only within cells, recent studies from our groups
and others have demonstrated that miRNAs can be
exported from cells (4–6). MicroRNAs are found in
many bodily ﬂuids, including circulating blood and
urine. Moreover, extracellular miRNAs are stable due
to binding with microparticles. These extracellular
miRNAs may enter into other tissues and cells to
serve as novel cell-to-cell communicators (7).SEE PAGE 2538MicroRNA-223 is a hematopoietic lineage, cell-
speciﬁc miRNA. Recent studies have revealed that
miR-223 is nearly exclusively expressed in hemato-
poietic cells at bone marrow and in bone marrow–
derived blood cells, mainly in blood platelets and
leukocytes, and has a low level in red blood cells (8).
Although vascular cells should have no endogenous
miR-223 expression, a signiﬁcant amount of miR-223
has been identiﬁed in normal vascular walls, as has
been demonstrated previously (9).
We hypothesized that miR-223 could be secreted
into the circulating blood by bone marrow–derived
blood cells such as platelets and leukocytes. The
blood cell–secreted miR-223 could enter into vascular
smooth muscle cells (VSMCs) as a novel endocrine
genetic signal to regulate their functions and begin
atherogenesis via its target genes. If veriﬁed, miR-223
might be a novel link between the inﬂammatory
blood cells and vascular cells that control vascular cell
functions and the development of vascular disease.
METHODS
VSMCs from the aortas of male Sprague-Dawley rats
were cultured with Dulbecco’s modiﬁed Eagle’s me-
dium containing 10% fetal bovine serum. For the
platelet study, mouse (C57BL/6) platelets were iso-
lated using platelet-rich plasma and the gel ﬁltration
method (10). For the leukocyte study, mouse mono-
cytes from blood were used and isolated as previously
described (11). We also used human monocytic cell
line THP-1 cells (ATCC, Manassas, Virginia).
Microparticles from serum were isolated by ultra-
centrifugation (4,5). RNAs were isolated with a
reagent (TRIzol, Life Technologies, Carlsbad, Califor-
nia) (5,9). Levels of miRNAs and messenger RNAs
were determined by real-time reverse transcription-polymerase chain reaction (qRT-PCR). The
absolute quantiﬁcation of a miRNA was on
the basis of qRT-PCR and a standard curve
using a series of concentrations of synthe-
sized mature miRNA (4,5), which were
expressed as picomoles per liter, copies per
cell, or copies per 15-pg tissue RNA.
The proﬁles of miRNAs in serum, blood
cells (platelets and leukocytes), and blood
microparticles were performed using Rodent
MicroRNA low-density array, whereas hu-
man miRNA proﬁling was performed using a
human low-density array (both TaqMan,
Life Technologies).The expression of miR-223 was down-regulated
by its inhibitor and up-regulated via its mimics.
Culture medium was collected before and after
12 h of THP-1 macrophage culture, and miR-223 levels
in the collected medium were determined. In addi-
tion, the collected medium after 12 h of THP-1 ma-
crophage culture was added to the cultured medium
of VSMCs. After 12 h, levels of miR-223 in VSMCs
were determined.
THP-1 macrophages were seeded in the upper
chamber of a co-culture system and then transfected
with Cy3-marked miR-223. VSMCs were added into
the lower chamber. Secretion of Cy3-marked miR-223
and its ability to enter into VSMCs were monitored by
ﬂuorescence microscopy.
In vivo, mice miR-223 expression was knocked
down by the locked nucleic acid miRNA inhibitor for
miR-223 (LN-anti-miR-223) (30 mg/kg, intraperito-
neal, biweekly; Exiqon, Vedbaek, Denmark).
ASSAYS AND ANALYSIS. Proteins were isolated from
cultured VSMCs and determined by Western blot
analysis using antibodies for the insulin-like growth
factor-1 receptor (IGF-1R), Akt, and phospho-Akt
(Cell Signaling Technology, Danvers, Massachusetts).
Glyceraldehyde-3-phosphate dehydrogenase anti-
body was used as a loading control.
A fragment of the 30-untranslated region (UTR) of
IGF-1R mRNA, which contained the conserved miR-
223 binding sequence with a ﬁreﬂy luciferase re-
porter, was transfected into HEK 293 cells. The cells
were co-transfected with a vehicle, an empty plasmid
(pDNR-CMV), and a plasmid expressing miR-223
(pmiR-223). Relative luciferase activity was measured.
VSMC proliferationwas induced by platelet-derived
growth factor (PDGF) (20 ng/ml) and determined by
MTT assay and 5-ethynyl-20-deoxyuridine assay (12).
VSMCmigrationwas determined by amodiﬁed Boyden
chamber assay (12), and VSMC apoptosis in cultured
cells was measured by terminal deoxynucleotidyl
transferase dUTP nick end labeling assay (12).
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platelet depletion models in male wild-type C57BL/6
mice (3 months old) were used as described previ-
ously (13,14).
Atherosclerosis was induced in the aortas of
apolipoprotein E (apoE) knockout male mice on a
C57BL/6 background (The Jackson Laboratory, Bar
Harbor, Maine) by giving them a Western diet (13).
Atherosclerotic lesions were measured by oil red O
staining using en face preparation of whole aortas
(13,14). Carotid artery balloon injury was induced in
male Sprague-Dawley rats (230 to 300 g) as previously
described (9).
Right carotid artery ligation injury was induced
in male wild-type C57BL/6 mice and age-matched
miR-223 knockout mice as described in our previous
study (15).
Morphometric analysis via computerized image
analysis system (NIS Elements BR 3.0, Nikon In-
struments, Inc., Melville, New York) was performed in
sections with hematoxilyn and eosin staining (9,15).
All animal protocols were approved by the Institu-
tional Animal Care and Use Committee at Rush Uni-
versity andwere consistent with the Guide for the Care
and Use of Laboratory Animals (updated version of the
National Institutes of Health guidelines, 2011). The
study was also approved by the research ethics com-
mittee of the Sun Yat-sen University and performed in
accordance with the Declaration of Helsinki. Human
serum samples were from healthy subjects (n ¼ 8) and
from patients with atherosclerosis (n ¼ 8). The
atherosclerotic arteries (n ¼ 6) were obtained from
patients with arteriosclerosis obliterans, and the
normal lower limb artery samples (n¼6)were acquired
from donors without arteriosclerosis obliterans. All
subjects provided written informed consent.
STATISTICAL ANALYSIS. All data are presented as
mean  SE. For relative gene expression, the mean
value of the vehicle control group is deﬁned as 100%
or 1. Two-tailed unpaired Student t tests and analyses
of variance were used for statistical evaluation of the
data. SPSS (version 17.0; IBM, Armonk, New York) was
used for data analysis. A p value < 0.05 was consid-
ered signiﬁcant.
Additional methodological details are described
in the Online Appendix.
RESULTS
The results of the miRNA arrays demonstrated that
miR-223 is the most abundant miRNA in platelets,
leukocytes (monocytes), and blood microparticles
from humans, mice, and rats. The 5 most abundant
miRNAs in mice are shown in Online Table 1. Theorigins of isolated microparticles from serum were
discriminated by ﬂow cytometry according to the
expression of membrane-speciﬁc antigens. The ma-
jority of circulating microparticles were from plate-
lets, followed by leukocytes and endothelial cells
(Figure 1A); the remainder (18%) were from other
sources.
The expression levels of miRNA in mouse and rat
serum were proﬁled by miRNA arrays. The top 5
miRNAs (Online Table 2) in serum were further veri-
ﬁed by qRT-PCR. To increase the translational feature
of our study, we determined the miRNA proﬁle in
normal human serum samples. (The top 5 miRNAs in
human serum are listed in Online Table 2.) Clearly,
miR-223 was the most abundant miRNA in both
animal and human serum.
To identify the distribution of extracellular miR-223
in blood, mouse serum was divided into 2 parts, su-
pernatant and microparticle, as described previously
(4,5), and the majority of the miR-223 was located in
the latter (Figure 1B). To assess the stability of miR-223,
the levels of miR-223 were determined immediately
and 24 h later at 4C. MicroRNA-223 in microparticles
was very stable (Figure 1C), unlike the miR-223 outside
the microparticles, which was not stable.
As shown in Figure 1D, it was difﬁcult to ﬁnd miR-
223 in passaged VSMCs cultured with serum-free
medium by qRT-PCR (fetal bovine serum had a high
level of miR-223). Its cycle threshold level was very
close to water control (negative control). The nega-
tive result of miR-223 in passaged VSMCs was not
related to their growth status, because the PDGF
stimulation did not change miR-223 levels in serum-
free cultured VSMCs (Figure 1E). However, a signiﬁ-
cant amount of miR-223 was identiﬁed in freshly
isolated VSMCs and in normal vascular walls
(Figures 1F and 1G). For further conﬁrmation, we
determined the absolute quantiﬁcation of miR-223,
miR-222 (an abundant miRNA in VSMCs and ves-
sels), and miR-34a (another well-studied miRNA
in VSMCs and vessels) in these cells and vessels.
Again, a signiﬁcant amount of miR-223 was found in
freshly isolated VSMCs and in normal vascular walls
(Figures 1I and 1J), but was not found in passaged
VSMCs (Figure 1H). In freshly isolated VSMCs and in
normal vascular walls, the levels of miR-223 were
lower than the abundant levels of miR-222, but was
similar to the levels of miR-34a (Figures 1I and 1J).
To test whether blood cells could secrete miR-223
into the extracellular space, THP-1 macrophages
were seeded into cell culture wells with different cell
numbers but with a ﬁxed amount of serum-free me-
dium. At 12 h after culture, miR-223 levels in the
medium were determined. No miR-223 was found in
FIGURE 1 miR-223 in Circulating Serum, VSMCs, and Vessels
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FIGURE 2 Blood C
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2530the medium without THP-1 macrophages. However, a
signiﬁcant amount of miR-223 was identiﬁed in THP-1
macrophage-cultured medium (Figure 2A). These
culture media were then added into the VSMC culture
medium. At 12 h after culture, the VSMCs were
collected to determine the levels of miR-223 inside
the VSMCs. Blood cell–secreted miR-223 could enter
into VSMCs, as demonstrated by the increased levels
of miR-223 in these VSMCs, which were cultured with
miR-223-containing medium (Figure 2B). To provide
direct evidence that the blood cell–released miR-223
could enter into VSMCs apart from the blood cells, a
co-culture system (Transwell, Corning, Tewksbury,ell–Secreted miR-223 in Extracellular Space, VSMCs, and Vascular Walls
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upper chamber, THP-1 macrophages were trans-
fected with Cy3-marked miR-223. VSMCs were added
into the lower chamber. The THP-1 macrophage-
released, Cy3-marked miR-223 could enter the VSMCs
(Figure 2C), although these 2 groups of different cells
did not contact each other. To test whether serum
miR-223 could enter the VSMCs, fresh serum isolated
from rats was added into the culture medium (at 10%)
of VSMCs for 24 h. The results revealed that the
serum miR-223 could enter VSMCs (Figure 2D).
To further verify these ﬁndings with regard to miR-
223 sources and mobility, we applied mouse modelsControl
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2531of leukocyte (neutrophil) or platelet depletion. As
expected, the leukocytes or platelets in blood were
successfully depleted by their special antibodies, as
evidenced by the decreased numbers of these blood
cells in mice (Figures 2E and 2F). Seven days after
depletion, the serum and aortas from these mice were
collected to measure the miR-223 levels, which were
signiﬁcantly decreased in mice with the depletion
of leukocytes or platelets (Figures 2G and 2H).
The results suggest that blood cells are the major
source of miR-223 in serum and vascular walls.FIGURE 3 miR-223 Levels from Subjects With Atherosclerosis and in
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2532artery balloon injury (Figure 3F), mouse carotid artery
ligation injury (Figure 3G), mouse atherosclerotic
aorta (Figure 3H), and human atherosclerotic artery
(Figure 3I) were conﬁrmed by histology.
The effects of miR-223 on VSMC proliferation,
migration, and apoptosis were determined using our
well-established cell models. Because VSMCs have
no or negligible endogenous miR-223, we could only
use the gain-of-function approach to test them.Functions of miR-223 in VSMCs
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migration in a dose-dependent manner (Figures 4D
and 4E). In contrast, miR-223 overexpression signiﬁ-
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2533Computational analysis suggested that human
IGF-1R has a miR-223 binding site in its 30-UTR, which
is conserved in mice, rats, and humans (Figure 5A).
IGF-1R is thus a potential direct target gene in VSMCs.
To test this, the miR-223 mimic was transfected
into VSMCs, and the IGF-1R expression was deter-
mined at both the protein and mRNA levels. The
expression of IGF-1R was down-regulated in VSMCs
(Figures 5B to 5D).
To further conﬁrm that miR-223 is able to directly
bind to IGF-1R and inhibit its expression, a fragment
of the 30-UTR of IGF-1R mRNA that contained the
conserved miR-223 binding sequence was cloned into
a ﬁreﬂy luciferase reporter construct and was trans-
fected into HEK 293 cells. As expected, pmiR-223,
but not pDNR-CMV, the empty control plasmid,FIGURE 5 IGF-1R/PI3K-Akt: Downstream Signaling Pathway of miR-
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FIGURE 6 Effects of miR-223 on Atherogenesis
120
80
40
0
Scramble Control
LN-Anti-miR-223
Scramble 
Control
Wild Type Control miR-223 Knockout Mice
Scramble 
Control
Scramble 
Control
LN-Anti-miR-233 LN-Anti-miR-233
LN-Anti-miR-233
Re
la
tiv
e 
m
iR
-2
23
Le
ve
ls
 in
 S
er
um
 (%
)
Re
la
tiv
e 
m
iR
-2
23
Le
ve
ls
 in
 A
rt
er
ie
s (
%
)
At
he
ro
sc
le
ro
tic
 A
re
a 
(%
)
120
20
*
*
*15
10
5
0
80
40
0
A
C D
E F
B
Wild Type
Control
miR-223 Knockout
Mice
In
tim
al
-t
o-
M
ed
ia
l A
re
a 
Ra
tio 1.0
0.8
0.6
0.4
0.2
0.0
*
(A) Serum levels and (B) vascular levels of miR-223 inmice were knocked down by locked nucleic acidmiRNA inhibitor for miR-223 (LN-anti-miR-
223; 30 mg/kg intraperitoneally biweekly). (C) Atherosclerotic lesion areas (red color by oil red O staining) in aortas from apolipoprotein-E
knockout mice treated with LN-anti-miR-223 or scramble control. (D) MicroRNA-223 inhibition by LN-anti-miR-223 signiﬁcantly increased
atherosclerotic lesion areas in apolipoprotein-E knockout mice with a Western diet. (E) Vascular neointimal lesion growth in miR-223 knockout
mice was signiﬁcantly increased compared with wild-type control mice in a model of carotid artery ligation injury. (F) Vascular neointimal
formation in carotid arteries from wild-type C57BL/6 mice and miR-223 knockout mice. *p < 0.05 compared with control groups. Abbreviations
as in Figures 1 and 3.
Shan et al. J A C C V O L . 6 5 , N O . 2 3 , 2 0 1 5
Blood Cell–Secreted miR-223 in Atherogenesis J U N E 1 6 , 2 0 1 5 : 2 5 2 6 – 3 7
2534shown by the decreased expression of p-Akt
(Figures 5H and 5I).
To test miR-223 effects on atherosclerosis, we
applied a well-established mouse atherosclerosis
model, in which atherosclerotic lesions were induced
in apoE knockout mice by a Western diet. We
conﬁrmed that LN-anti-miR-223 (30 mg/kg), given
both intravenously (tail vein) (Online Figures 1 and 2)
or intraperitoneally (Figures 6A and 6B) biweekly
could successfully knock down the miR-223 both in
serum and vascular walls. We thus applied an intra-
peritoneal approach in this study. Our results
demonstrated that miR-223 inhibition signiﬁcantlyincreased atherogenesis, as shown by the increased
atherosclerotic area determined via oil red O staining
(Figures 6C and 6D).
To verify the effect of miR-223 on atherogenesis,
miR-223 knockout mice were used, with miR-223
knockout conﬁrmed by qRT-PCR (Online Figure 3).
To induce vascular neointimal growth, carotid artery
ligation injury was performed in miR-223 knockout
mice and in wild-type mice of the same age. Histo-
logical analysis revealed that the vascular neointimal
growth in knockout mice at 4 weeks post-ligation
injury was signiﬁcantly increased compared with
that in wild-type mice (Figures 6E and 6F).
CENTRAL ILLUSTRATION Blood Cell–Secreted miR-223 in Atherosclerotic Vascular Disease
Shan, Z. et al. J Am Coll Cardiol. 2015; 65(23):2526–37.
Inﬂammatory blood cells, such as leukocytes and platelets, which are originally from hematopoietic cells in bone marrow, can secrete the hematopoietic lineage, cell-
speciﬁc micro-ribonucleic acid (miR)-223 into circulating serum. This miR-223 can then enter vascular cells (e.g., vascular smooth muscle cells [VSMCs] and vascular
walls) and work as a novel endocrine genetic signal (like a hormone) in VSMCs to regulate their biological functions, such as proliferation, migration, and apoptosis via
target genes such as insulin-like growth factor 1 receptor (IGF-1R) and the P13K-Akt pathway. Under pathological conditions, such as atherosclerosis and vascular
injury, blood cells release more miR-223, which results in increased levels of miR-223 in VSMCs and vascular walls. The increased miR-223 helps protect against
atherosclerotic vascular disease (vascular neointimal formation and atherosclerosis). P ¼ phosphate.
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2536DISCUSSION
MicroRNA-223 is a hematopoietic lineage, cell-
speciﬁc miRNA. Theoretically, VSMCs should not
produce or generate only negligible amounts of
endogenous miR-223. The negative result was not
induced by growth stopping under the serum-free
condition, because in PDGF-stimulated, proliferative
VSMCs, miR-223 still could not be detected. However,
a signiﬁcant amount of miR-223 could be found both
in freshly isolated VSMCs and in normal vascular
walls, but this miR-223 should mainly be from other
sources. In this study, we found that blood cell–
secreted miR-223 in serum could enter VSMCs, and
that bone marrow–derived blood cells are the major
sources of miR-223 in VSMCs and vascular walls.
More importantly, we identiﬁed that the extra-
cellular serum miR-223 could not only enter into
VSMCs, but also had strong biological functions
in VSMCs via its target gene. Only 2 previous
studies sought to determine the biological roles of
miR-223 in VSMCs, but for unclear reasons, they
reached opposite conclusions (17,18). In this study,
we identiﬁed that miR-223 had antiproliferative and
antimigratory effects on VSMCs. No previous study
has tested the effect of miR-223 on VSMC apoptosis,
but we identiﬁed that overexpression of miR-223
via a miR-223 mimic markedly enhanced VSMC
apoptosis.
It is well known that miRNA obtains its cellular
effects via its multiple target genes. Previous studies
have suggested that IGF-1R could be a direct target
gene of miR-223 (16). In this study, IGF-1R was a
target gene of miR-223, and along with its down-
stream signaling pathway PI3K-Akt, was involved
in miR-223–mediated effects on VSMCs (Central
Illustration). Other potential target genes from bioin-
formatics analysis (e.g., CDH11 and 14-3-3-gamma,
which are involved in miR-223–mediated effects)
should be tested in future studies.
It is well established that VSMC proliferation,
migration, and apoptosis are key cellular events
in atherosclerosis development. Because miR-223 had
strong effects on these cellular events of VSMCs,
we hypothesized that miR-223 might play a role in
atherogenesis, and found that miR-223 in serum and
arteries from atherosclerotic mice and patients were
signiﬁcantly higher than those from normal control
subjects. Interestingly, the atherosclerotic lesions
in apoE knockout mice on a Western diet were
signiﬁcantly exacerbated by miR-223 knockdown.
Thus, increased miR-223 might help protect against
atherosclerosis. This protective role in athero-
genesis has been identiﬁed in other miRNAs, such asexogenous miR-145, a down-regulated miRNA in hu-
man atherosclerotic lesions (19).
Although we focused on VSMCs, blood cell–
secreted miR-223 may also enter other vascular cells.
Recent studies have found that high-density
lipoprotein–binding miR-223 is able to enter other
cells, including vascular endothelial cells, without
endogenous miR-223 (20,21). However, the exoge-
nous miR-223 delivered via high-density lipoprotein
reduces expression of intercellular adhesion mole-
cule 1 in endothelial cells (21).
Finally, to verify the role of miR-223 in atherogen-
esis, we assessed vascular neointimal lesion formation
induced by carotid artery ligation in miR-223 knockout
mice. Compared with that in wild-type mice, the
vascular neointimal formation in miR-223 deﬁcient
mice was markedly increased. The result regarding the
effect of miR-223 on vascular neointimal growth from
a gene knockout approach was consistent with that
from pharmacological approaches on atherogenesis.
STUDY LIMITATIONS. The biological functions of
miR-223 in other vascular cells and in blood inﬂam-
matory cells should be tested in future studies. In
addition, cross-breeding of Apo E knockout mice with
miR-223 knockout or miR-223 transgenic mice will
provide additional evidence for the role of miR-223 in
atherogenesis.
CONCLUSIONS
On the basis of our ﬁndings, inﬂammatory blood cells,
such as leukocytes and platelets that are originally from
hematopoietic cells in bone marrow, can secrete he-
matopoietic lineage, cell-speciﬁc miR-223 into circu-
lating serum. This miR-223 could then enter vascular
cells, such as VSMCs and vascular walls, and work as a
novel endocrine genetic signal (like a hormone) in
VSMCs to regulate biological functions, such as prolif-
eration, migration, and apoptosis. Under pathological
conditions, such as atherosclerosis and vascular in-
juries, blood cells are activated to release more miR-223
into serum and subsequently increase miR-223 levels in
VSMCs and vascular walls, which helps protect against
atherogenesis.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Micro-
RNAs, such as miR-223, which are secreted from blood
cells that modulate genetic endocrine signals in bone
marrow, circulating inﬂammatory cells, and vascular tis-
sue, may play a role in atherosclerosis.
TRANSLATIONAL OUTLOOK: Future studies should
aim to deﬁne the role of blood cell–secreted miRNAs in
atherosclerosis and explore the potential therapeutic
value of interventions that inﬂuence their activity in pa-
tients at risk of atherosclerosis.
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